Moreover, imaging and genetic examination may provide further insight into the mechanisms underlying these conditions thereby opening novel therapeutic avenues as has been the case with FCD type II (mTOR inhibitors) and MOGHE (oral galactose supplementation). This evidence concerns the gene MTOR and isolated focal cortical dysplasia type II.